Grants and Contracts Details
Description
Enterococci represent one of the leading causes of infections among hospitalized patients and
residents of long-term care facilities. In the USA, there were over 50,000 cases of enterococcal
infections in 2017, with ~10% fatality rate. The majority of infections are caused by
Enterococcus faecalis and E. faecium, which include bacteremia, urinary tract and surgical sites
infections, and endocarditis. E. faecalis and E. faecium display high levels of natural and
acquired antibiotic resistance that severely limits the treatment options. In Enterococci, one of
the major components of cell wall is the Enterococcal Polysaccharide Antigen (EPA). The
recently solved structure of EPA polymer consists of a polyrhamnose backbone decorated with
wall teichoic acids. While the putative mechanism of EPA biosynthesis has been proposed, the
critical steps of this mechanism remain poorly defined. The goal of this application is to decipher
the mechanism of initiation of polyrhamnose and wall teichoic acid assembly. In addition, we will
examine the role of EPA in the resistance mechanism to daptomycin, the antibiotic of last resort.
We will utilize a combination of genetic, analytical and biochemical methods to answer these
questions. The proposed experiments will provide a better understanding of cell wall biogenesis
in Enterococci to enable the development of alternative approaches to treat drug-resistant
infections. EPA has been proposed as a vaccine candidate whereas the enzymes of the EPA
biogenesis represent attractive drug targets, therefore the proposed studies will have implication
for the vaccine and drug development.
Status | Active |
---|---|
Effective start/end date | 5/20/22 → 4/30/25 |
Funding
- National Institute of Allergy and Infectious Diseases: $403,638.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.